| Name | Title | Contact Details |
|---|
LTS offers a wealth of experience in adhesive formulation and coating technology to manufacture and supply specialty laminates intermediates for many applications. Our products are tailored to our customers' needs and are targeted for use in
Aurora Cannabis Inc. is a world-renowned integrated cannabis company with an industry-leading reputation for continuously elevating and setting the global cannabis industry standard. Through our wholly owned subsidiaries, strategic investments, and global partnerships, Aurora provides a wide range of premium quality cannabis and hemp products and services, develops innovative technologies, promotes cannabis consumer health and wellness, and delivers an exceptional customer experience across all its brands. Aurora`s operations span multiple continents and focuses on both the medical and recreational cannabis production and sales, patient education and clinic counselling services, home hydroponic cultivation, extraction technologies and delivery systems, and hemp-based food health products. We operate around the globe pursuing new and emerging cannabis markets where possible through our owned network of import, export and wholesale distributors, and our e-commerce and mobile applications.
Acer Therapeutics is a biotech company, headquartered in Cambridge, MA, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. Acer`s lead candidate, EDVISO™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type Ehlers-Danlos syndrome (vEDS). Ehlers-Danlos Syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. vEDS is a subtype characterized by severe arterial dissections, ruptures and early death. Complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. Median age of death is estimated to be around 50 years. Patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the COL3A1 gene. There are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the U.S. (Pepin 2014). There are no specific pharmacological treatments for vEDS and medical intervention centers on symptomatic treatment, prophylactic measures and genetic counseling. Acer was awarded orphan drug designation by the FDA in January 2015. Acer`s second candidate, ACER-001, is the first pharmaceutical therapy being developed for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism. Approximately 800 patients suffer from MSUD in the U.S. and 3,000 worldwide. There are no therapeutic options for MSUD and diet is not enough. Despite careful dietary management, the majority of MSUD patients have chronic neurological and social impairment, as well as life-threatening episodes of intoxication. Acer was awarded orphan drug designation by the FDA in August 2014.
Allied Research International is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.